Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Cardiovascular disease causes over 17 million global deaths annually, with hypertension complications leading to 9.4 million deaths.
• Early hypertension detection and management can prevent severe complications like dialysis and cardiac surgery.
• While lifestyle changes are recommended, most patients require antihypertensive medications.

Purpose of the Study:

• To review current hypertension management strategies and guidelines.
• To discuss existing classes of antihypertensive medications and their mechanisms.
• To highlight the ongoing development of novel therapeutic agents for hypertension.

Main Methods:

• Review of global hypertension guidelines, including the 2020 International Society of Hypertension guidelines.
• Analysis of current pharmacological approaches targeting the renin-angiotensin-aldosterone system (RAAS), adrenergic receptors, calcium channels, and other pathways.
• Examination of emerging drug classes in phase III clinical trials.

Main Results:

• Established drug classes like RAAS inhibitors, calcium channel blockers, diuretics, and vasodilators are used for hypertension control.
• Despite current treatments, the global prevalence of hypertension remains high.
• Novel drug classes with different mechanisms of action are under investigation.

Conclusions:

• Effective management of hypertension is essential to reduce cardiovascular mortality.
• Existing therapies, while beneficial, have limitations in controlling the global hypertension epidemic.
• Emerging pharmacological interventions hold promise for improving blood pressure management and reducing the global burden of hypertension.